Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and severe immune-mediated disease that affects sensory ...
16hon MSN
Medicare will start covering obesity drugs for the first time. Here's what patients should know
The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results